Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker OA (osteoactivin) for detecting postmenopausal osteoporosis and kit of biomarker OA

An osteoporosis and biomarker technology, applied in the field of bioengineering, can solve the problems of women's physical harm and complex methods, and achieve the effect of avoiding radiation, obvious technical effect, high clinical application value and prospect.

Active Publication Date: 2021-02-09
SHANGHAI CITY PUDONG NEW AREA GONGLI HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The object of the present invention is to provide a biomarker-osteokine and its kit for detecting postmenopausal osteoporosis. Huosu and its kit should solve the technical problems that the methods for detecting postmenopausal osteoporosis in the prior art are complex and harmful to women's bodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker OA (osteoactivin) for detecting postmenopausal osteoporosis and kit of biomarker OA
  • Biomarker OA (osteoactivin) for detecting postmenopausal osteoporosis and kit of biomarker OA
  • Biomarker OA (osteoactivin) for detecting postmenopausal osteoporosis and kit of biomarker OA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] In order to study the pathogenesis of postmenopausal osteoporosis, the present invention selects postmenopausal female patients hospitalized for fractures in the Department of Orthopedics, Gongli Hospital, Pudong New District, Shanghai, and performs Lunar Prodigy dual-energy X-ray absorptiometry (GE Company of the United States) for detection. And according to the bone density T value, they were divided into normal bone mass group (N) (T>-1) and osteoporosis group (O) (T<-2.5), with 5 people in each group. (This patent application has been approved by the Hospital Ethics Committee)

[0025] The patient's peripheral blood sample was taken, and the white blood cells were separated to extract RNA, and the whole transcriptome sequencing (RNA-Seq) was performed (performed by Shanghai Ouyi Biomedical Technology Co., Ltd.). The results showed that compared with the normal bone mass group, there were 187 mRNAs with statistically significant expression differences of more than 2...

Embodiment 2

[0028] In view of the important regulatory effect of free CD14+ monocytes in peripheral blood on the differentiation of osteoclast precursor cells to bone metabolism, the present invention selects postmenopausal women with normal bone mass and osteoporosis, extracts peripheral blood samples, and uses Ficoll density Gradient centrifugation was used to separate and obtain peripheral blood mononuclear cells (PBMC), and further immunomagnetic bead sorting was used to obtain CD14 + Monocytes; OCP in vitro TM BulletKit TM After culture and expansion in special medium for osteoclast precursor cells, RNA and protein were extracted and detected by qRT-PCR, Western blot and flow cytometry. The results showed that peripheral blood CD14 in postmenopausal women with osteoporosis + monocyte OA mRNA ( image 3 A) and protein ( image 3 B, C) The expression levels were significantly decreased.

Embodiment 3

[0030] To make mice OVX osteoporosis group and sham operation (Sham) group model, MicroCT ( Figure 4 A) and HE staining ( Figure 4 B) Verify that the modeling was successful. Flow cytometry analysis showed that CD14 + The expression level of OA protein in monocytes decreased significantly ( Figure 5 A and 5B).

[0031] Example 3

[0032] When the level of estrogen decreases, OA negatively regulates the function of Th17 cells and inhibits the abnormal activation of osteoclasts, which plays an important regulatory role in postmenopausal osteoporosis.

[0033] Studies have shown that: first, under in vitro induced differentiation conditions, low expression of OA can promote CD14 + Monocytes differentiate into osteoclasts ( Figure 6 , 7 );

[0034] Sorted osteoporosis group (O) peripheral blood CD14 + Monocytes were induced by adding RANKL (30 ng / ml) and M-CSF (30 ng / ml) in vitro, and the number of TRAP-positive cells was found ( Figure 6 A) and bone resorption area...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of OA (osteoactivin) on the surfaces of peripheral blood CD14<+> mononuclear cells in preparation of a biomarker for detecting postmenopausal osteoporosis, and also provides a kit for detecting the postmenopausal osteoporosis. The kit contains a reagent for detecting OA on the surfaces of the peripheral blood CD14<+> mononuclear cells. According to the invention, early diagnosis molecules OA on the surface of the peripheral blood CD14<+> mononuclear cells of the postmenopausal osteoporosis are discovered and OA negatively regulates the molecular mechanismof RANKL<+>Th17 cells in abnormal activation of osteoclasts of the postmenopausal osteoporosis. Compared with imaging examination, the method for detecting the relative content of the OA on the surfaces of the peripheral blood CD14<+> mononuclear cells has the advantage that the postmenopausal osteoporosis can be rapidly, conveniently and accurately diagnosed in the early stage at the molecular level, so that not only can the postmenopausal osteoporosis of a patient be detected in the early stage, but also the patient can be prevented from receiving X-ray radiation in the bone mineral densitydetection process.

Description

technical field [0001] The invention belongs to the field of bioengineering, and relates to a biomarker and a diagnostic kit, in particular to a biomarker osteolyn and a kit for detecting postmenopausal osteoporosis. Background technique [0002] Osteoporosis is a systemic, metabolic skeletal disease characterized by decreased bone mass, degeneration of bone microarchitecture, decreased bone strength, increased bone fragility, and increased risk of fracture. In postmenopausal women, due to the sudden drop in estrogen levels in the body, initially, the activity of osteoclasts increases and apoptosis decreases, causing rapid bone loss; then, the activity of osteoblasts decreases, resulting in long-term, slow bone loss and thinning of trabecular bone , reduction, hypomineralization, and decreased bone strength, leading to postmenopausal osteoporosis, which seriously endangers women's health and brings huge economic and social burdens. But so far, its exact mechanism is still u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883G01N33/6893C12Q2600/158G01N2800/108G01N2333/47
Inventor 邵进陈天宁孔德策
Owner SHANGHAI CITY PUDONG NEW AREA GONGLI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com